Pharma
Trevia (Sitagliptin Tablets USP 50 mg)
DPP-4 inhibitor; 50 mg Sitagliptin tablets for the management of Type 2 Diabetes.
Trevia (Sitagliptin Tablets USP 50 mg)
Trevia contains Sitagliptin, an orally-active dipeptidyl peptidase-4 (DPP-4) inhibitor used to improve glycemic control in adults with type 2 diabetes mellitus. It works by increasing the levels of natural substances called incretins, which help control blood sugar by increasing insulin release, especially after a meal, and decreasing the amount of sugar made by the liver. It is typically used as an adjunct to diet and exercise. Trevia is not for use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. Common side effects may include upper respiratory tract infection, nasopharyngitis, and headache.
You May Also Like
Combination DPP-4 inhibitor and Biguanide; 50 mg/500 mg Sitagliptin/Metformin tablets for Type 2 Diabetes management.
Combination DPP-4 inhibitor and Biguanide; 50 mg/1000 mg Sitagliptin/Metformin tablets for Type 2 Diabetes management.
Combination DPP-4 inhibitor and Biguanide; 50mg/500mg Vildagliptin/Metformin tablets for Type 2 Diabetes control.
Triple antidiabetic combo; Dapagliflozin 10 mg, Sitagliptin 100 mg, and Metformin ER 1000 mg (28 tablets) for Type 2 Diabetes.